Neurochemical mechanisms of tremor in Parkinson’s disease

Close metadata

Recommended articles:

Criteria of syndrome frailty in Parkinson´s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):52-56

Ginkgolide B: mechanisms of neurobiological effects, prospects for use in the therapy of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):22-27

Tremor-dominant form of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):28-35

Nocturia in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):48-54

Associations of serum neuromarkers with clinical features of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):145-152

The association of single-nucleotide polymorphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):82-88

Problems in organizing neurosurgical care for patients with Parkinson’s disease in the Russian Federation. Burdenko's Journal of Neurosurgery. 2024;(3):5-13

Recovery of consciousness under therapy with benzodiazepines. A case report and literature review. Burdenko's Journal of Neurosurgery. 2024;(3):81-89

Calcitonin gene-related peptide in pathophysiology of migraine. Russian Journal of Pain. 2024;(2):56-67

Treatment of atopic dermatitis considering assessment of neurotransmitters in blood. Russian Journal of Clinical Dermatology and Venereology. 2024;(4):368-376

Tremor is one of the main motor symptoms of Parkinson’s disease, and its pathophysiology remains largely unknown. The clinical and pathomorphological heterogeneity of tremor and the not always response to therapy complicate the task of researchers and clinicians. This review discusses the specific degeneration of neurotransmitter systems driving the development of tremor, and the influence of neurotransmitters on specific anatomical entities according to current models explaining tremor. It is discusses how changes in neurotransmitter systems may influence the clinical diversity of tremor and differences in response to therapy. Data from clinical trials demonstrating the effect of the dopamine receptor agonist piribedil on tremor are presented.

Keywords:

Parkinson’s disease

tremor

pathophysiology

neurotransmitters

piribedil

Authors:

Putyatin I.A.

Pirogov Russian National Research Medical University (Pirogovsky University)

ORCID: 0009-0009-2418-9577

Titova N.V.

Pirogov Russian National Research Medical University (Pirogovsky University);
Federal Center of Brain Research and Neurotechnologies

ORCID: 0000-0002-7044-3013

Received:

16.08.2024

Accepted:

20.08.2024

List of references:

Heusinkveld LE, Hacker ML, Turchan M, et al. Impact of Tremor on Patients With Early Stage Parkinson’s Disease. Front Neurol. 2018;9:628. https://doi.org/10.3389/fneur.2018.00628
Levin OS, Illarioshkin SN, Golubev VL. Ekstrapiramidnye sindromy. M.: MEDpress-inform; 2022. (In Russ.).
Koh SB, Kwon DY, Seo WK, et al. Dissociation of Cardinal Motor Signs in Parkinson’s Disease Patients. Eur Neurol. 2010;63(5):307-310. https://doi.org/10.1159/000314179
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284-2303. https://doi.org/10.1016/S0140-6736(21)00218-X
Gupta DK, Marano M, Zweber C, et al. Prevalence and Relationship of Rest Tremor and Action Tremor in Parkinson’s Disease. Tremor and Other Hyperkinetic Movements. 2020;10(1):58-61. https://doi.org/10.5334/tohm.552
Dirkx MF, Zach H, Bloem BR, et al. The nature of postural tremor in Parkinson disease. Neurology. 2018;90(13):e1095-e1103. https://doi.org/10.1212/WNL.0000000000005215
Marras C, Chaudhuri KR, Titova N, Mestre TA. Therapy of Parkinson’s Disease Subtypes. Neurotherapeutics. 2020;23(7):34-39. https://doi.org/10.1007/s13311-020-00894-7
Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: Comparison with the unified Parkinson’s disease rating scale. Movement Disorders. 2013;28(5):668-670. https://doi.org/10.1002/mds.25383
Schiess MC, Zheng H, Soukup VM, et al. Parkinson’s disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinson Rel Dis. 2000;6(2):69-76. https://doi.org/10.1016/s1353-8020(99)00051-6
Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson’s disease. Brain. 2009;132(11):2947-2957. https://doi.org/10.1093/brain/awp234
Kipfer S. Resting Tremor in Parkinson Disease. Arch Neurol. 2011;68(8):1037. https://doi.org/10.1001/archneurol.2011.147
Nonnekes J, Timmer MHM, de Vries NM, et al. Unmasking levodopa resistance in Parkinson’s disease. Mov Dis. 2016;31(11):1602-1609. https://doi.org/10.1002/mds.26712
Levin OS, Datieva VK. Tremor in Parkinson’s disease: features of phenomenology and treatment. Modern Therapy in Psychiatry and Neurology. 2014;3:14-19. (In Russ.).
Bril EV, Belova EM, Sedov AS, et al. Current understanding of neurostimulation for Parkinson’s disease. Annals of Clinical and Experimental Neurology. 2022;16(2):89-99. (In Russ.). https://doi.org/10.54101/acen.2022.2.10
Boonstra JT, McGurran H, Temel Y, Jahanshahi A. Nigral neuropathology of Parkinson’s motor subtypes coincide with circuitopathies: a scoping review. Brain Struct Funct. 2022;227(7):2231-2242. https://doi.org/10.1007/s00429-022-02531-9
Cagnan H, Little S, Foltynie T, et al. The nature of tremor circuits in parkinsonian and essential tremor. Brain. 2014;137(12):3223-3234. https://doi.org/10.1093/brain/awu250
McGregor MM, Nelson AB. Circuit Mechanisms of Parkinson’s Disease. Neuron. 2019;101(6):1042-1056. https://doi.org/10.1016/j.neuron.2019.03.004
Nambu A, Tachibana Y. Mechanism of parkinsonian neuronal oscillations in the primate basal ganglia: some considerations based on our recent work. Front Syst Neurosci. 2014;8:74. https://doi.org/10.3389/fnsys.2014.00074
Helmich RC, Toni I, Deuschl G, Bloem BR. The Pathophysiology of Essential Tremor and Parkinson’s Tremor. Curr Neurol Neurosci Rep. 2013;13(9):378. https://doi.org/10.1007/s11910-013-0378-8
Dirkx MF, Bologna M. The pathophysiology of Parkinson’s disease tremor. J Neurol Sci. 2022;435:120196. https://doi.org/10.1016/j.jns.2022.120196
Pineda-Pardo JA, Sánchez‐Ferro Á, Mariana H, et al. Onset pattern of nigrostriatal denervation in early Parkinson’s disease. Brain. 2022;145(3):1018-1028. https://doi.org/10.1093/brain/awab378
Yang Z, Xie Y, Dou K, et al. Associations of striatal dopamine transporter binding with motor and non‐motor symptoms in early Parkinson’s disease. Clin Transl Sci. 2023;16(6):1021-1038. https://doi.org/10.1111/cts.13508
Fan Kangli, Zhao H, Li Y, et al. Characteristics and influencing factors of 11C-CFT PET imaging in patients with early and late onset Parkinson’s disease. Front Neurol. 2023;14:23-29. https://doi.org/10.3389/fneur.2023.1195577
Nagae LM, Honce JM, Tanabe J, et al. Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes. Front Neuroanatomy. 2016;10:34-39. https://doi.org/10.3389/fnana.2016.00017
Rinne JO, Mlic JR, Paljärvi L, Rinne UK. Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol. 1989;26(1):47-50. https://doi.org/10.1002/ana.410260107
Fearnley JM, Lees AJ. Ageing and parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(5):2283-2301. https://doi.org/10.1093/brain/114.5.2283
Jellinger KA. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Mov Dis. 2011;27(1):8-30. https://doi.org/10.1002/mds.23795
Jellinger KA. Post mortem studies in Parkinson’s disease — is it possible to detect brain areas for specific symptoms? J Neur Trans. 1999;23:1-29. https://doi.org/10.1007/978-3-7091-6360-3_1
Halliday GM, McRitchie DA, Cartwright H, et al. Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease. J Clin Neurosci. 1996;3(1):52-60. https://doi.org/10.1016/s0967-5868(96)90083-1
Geibl FF, Henrich MT, Oertel WH. Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease. J Neural Trans. 2019;126(4):377-396. https://doi.org/10.1007/s00702-019-01970-9
Jellinger KA, Paulus W. Clinico-pathological correlations in Parkinson’s disease. Clin Neurol Neurosurg. 1992;94:86-88. https://doi.org/10.1016/0303-8467(92)90033-y
Jan C, François C, Tandé D, et al. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. European J Neurosci. 2000;12(12):4525-4535.
François C, Savy C, Jan C, et al. Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson’s disease patients. J Comparat Neurol. 2000;425(1):121-129. https://doi.org/10.1002/1096-9861(20000911)425:1%3C121::aid-cne10%3E3.0.co;2-g
Helmich RC, Janssen MJR, Oyen WJG, et al. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol. 2011;69(2):269-281. https://doi.org/10.1002/ana.22361
Lee JY, Lao-Kaim NP, Pasquini J, et al. Pallidal dopaminergic denervation and rest tremor in early Parkinson’s disease: PPMI cohort analysis. Park Rel Dis. 2018;51:101-104. https://doi.org/10.1016/j.parkreldis.2018.02.039
Neumane S, Stéphanie Mounayar, Jan C, et al. Effects of dopamine and serotonin antagonist injections into the striatopallidal complex of asymptomatic MPTP-treated monkeys. Neurobiol Dis. 2012;48(1):27-39. https://doi.org/10.1016/j.nbd.2012.06.002
Rajput AH, Sitte HH, Rajput A, et al. Globus pallidus dopamine and Parkinson motor subtypes: Clinical and brain biochemical correlation. Neurology. 2008;70(16/2):1403-1410. https://doi.org/10.1212/01.wnl.0000285082.18969.3a
Garcia-Cabezas MA, Martinez-Sanchez P, Sanchez-Gonzalez MA, et al. Dopamine Innervation in the Thalamus: Monkey versus Rat. Cerebral Cortex. 2008;19(2):424-434. https://doi.org/10.1093/cercor/bhn093
Dirkx MF, den Ouden HEM, Aarts E, et al. Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus. Brain. 2017;140(3):aww331. https://doi.org/10.1093/brain/aww331
Pollok B, Makhloufi H, Butz M, et al. Levodopa affects functional brain networks in parkinsonian resting tremor. Mov Dis. 2008;24(1):91-98. https://doi.org/10.1002/mds.22318
Bostan AC, Strick PL. The basal ganglia and the cerebellum: nodes in an integrated network. Nat Rev Neurosci. 2018;19(6):338-350. https://doi.org/10.1038/s41583-018-0002-7
Shen B, Pan Y, Jiang X, et al. Altered putamen and cerebellum connectivity among different subtypes of Parkinson’s disease. CNS Neurosc Ther. 2019;26(2):207-214. https://doi.org/10.1111/cns.13259
Flace P, Livrea P, Basile GA, et al. The Cerebellar Dopaminergic System. Front Syst Neurosc. 2021;15:650614. https://doi.org/10.3389/fnsys.2021.650614
Dirkx MF, Zach H, van Nuland A, et al. Cerebral differences between dopamine-resistant and dopamine-responsive Parkinson’s tremor. Brain. 2019;142(10):3144-3157. https://doi.org/10.1093/brain/awz261
Buddhala C, Loftin SK, Kuley BM, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2015;2(10):949-959. https://doi.org/10.1002/acn3.246
Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson’s disease. Prog Neurobiol. 2011;95(2):163-212. https://doi.org/10.1016/j.pneurobio.2011.08.004
Wang J, Sun J, Gao L, et al. Common and unique dysconnectivity profiles of dorsal and median raphe in Parkinson’s disease. Human Brain Map. 2022;44(3):1070-1078. https://doi.org/10.1002/hbm.26139
Millot M, Saga Y, Duperrier S, et al. Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys. Neurobiol Dis. 2020;134:104643. https://doi.org/10.1016/j.nbd.2019.104643
Doder M, Rabiner EA, Turjanski N, et al. 11C-WAY 100635 PET study. Tremor in Parkinson’s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003;60(4):601-605. https://doi.org/10.1212/01.wnl.0000031424.51127.2b
Pasquini J, Ceravolo R, Qamhawi Z, et al. Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study. Brain. 2018;141(3):811-821. https://doi.org/10.1093/brain/awx376
Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study. J Neural Trans. 2008;115(5):721-729. https://doi.org/10.1007/s00702-007-0015-2
Zhong Y, Liu H, Liu G, et al. A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson’s disease. NPJ Park Dis. 2022;8(1):1-9. https://doi.org/10.1038/s41531-022-00347-2
Wang JY, Fan QY, He JH, et al. SLC6A4 Repeat and Single-Nucleotide Polymorphisms Are Associated With Depression and Rest Tremor in Parkinson’s Disease: An Exploratory Study. Front Neurol. 2019;10:34-39. https://doi.org/10.3389/fneur.2019.00333
Huang KW, Ochandarena NE, Philson AC, et al. Molecular and anatomical organization of the dorsal raphe nucleus. eLife. 2019;8:45-49. https://doi.org/10.7554/elife.46464
Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain. 2007;34(8):45-48. https://doi.org/10.1093/brain/awm239
Pagano G, Niccolini F, Politis M. The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies. J Neural Trans. 2017;125(8):1217-1223. https://doi.org/10.1007/s00702-017-1823-7
Muñoz A, Lopez-Lopez A, Labandeira CM, et al. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA. Front Neuroanat. 2020;14:26. https://doi.org/10.3389/fnana.2020.00026
Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Mov Dis Clin Pract. 2015;3(2):116-124. https://doi.org/10.1002/mdc3.12266
Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited. J Park Dis. 2023;13(2):127-144. https://doi.org/10.3233/JPD-225060
Vanover K, Betz A, Weber S, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008;90(4):540-544. https://doi.org/10.1016/j.pbb.2008.04.010
Vermeiren Y, Hirschberg Y, Mertens I, De Deyn PP. Biofluid Markers for Prodromal Parkinson’s Disease: Evidence From a Catecholaminergic Perspective. Front Neurol. 2020;11:595. https://doi.org/10.3389/fneur.2020.00595
Schwarz LA, Luo L. Organization of the Locus Coeruleus-Norepinephrine System. Curr Biol. 2015;25(21):R1051-R1056. https://doi.org/10.1016/j.cub.2015.09.039
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18(2):101-113. https://doi.org/10.1038/nrn.2016.178
Dirkx MF, Zach H, van Nuland AJ, et al. Cognitive load amplifies Parkinson’s tremor through excitatory network influences onto the thalamus. Brain. 2020;143(5):1498-1511. https://doi.org/10.1093/brain/awaa083
van der Heide A, Speckens AEM, Meinders MJ, et al. Stress and mindfulness in Parkinson’s disease — a survey in 5000 patients. NPJ Park Dis. 2021;7(1):1-10. https://doi.org/10.1038/s41531-020-00152-9
Samuels E, Szabadi E. Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part I: Principles of Functional Organisation. Cur Neuropharmacol. 2008;6(3):235-253. https://doi.org/10.2174/157015908785777229
Kinnerup MB, Sommerauer M, Damholdt MF, et al. Preserved noradrenergic function in Parkinson’s disease patients with rest tremor. Neurobiol Dis. 2021;152:105295. https://doi.org/10.1016/j.nbd.2021.105295
Nicoló Gabriele Pozzi, Bolzoni F, Biella G, et al. Brain Noradrenergic Innervation Supports the Development of Parkinson’s Tremor: A Study in a Reserpinized Rat Model. Cells. 2023;12(21):2529-2529. https://doi.org/10.3390/cells12212529
Nahimi A, Sommerauer M, Kinnerup MB, et al. Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER. J Nucl Med. 2017;59(4):659-664. https://doi.org/10.2967/jnumed.117.190975
Isaias IU, Marotta G, Gianni Pezzoli, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol. 2011;11(1):45-49. https://doi.org/10.1186/1471-2377-11-88
Pavese N, Rivero-Bosch M, Lewis SJ, et al. Progression of monoaminergic dysfunction in Parkinson’s disease: A longitudinal 18F-dopa PET study. NeuroImage. 2011;56(3):1463-1468. https://doi.org/10.1016/j.neuroimage.2011.03.012
Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, et al. The Noradrenergic System in Parkinson’s Disease. Front Pharmacol. 2020;11:56-59. https://doi.org/10.3389/fphar.2020.00435
Zhu MY, Ali S, Zhan Y, Fan Y. Norepinephrine upregulates the expression of tyrosine hydroxylase and protects dopaminegic neurons against 6-hydrodopamine toxicity. Neurochem Int. 2019;131:104549. https://doi.org/10.1016/j.neuint.2019.104549
Zach H, Dirkx MF, Pasman JW, et al. Cognitive Stress Reduces the Effect of Levodopa on Parkinson’s Resting Tremor. CNS Neurosci Ther. 2017;23(3):209-215. https://doi.org/10.1111/cns.12670
Helmich RC, Pattamon Panyakaew REK, et al. Cerebello‐Cortical Control of Tremor Rhythm and Amplitude in Parkinson’s Disease. Mov Dis. 2021;36(7):1727-1729. https://doi.org/10.1002/mds.28603
Bologna M, Rocchi L, Leodori G, et al. Cerebellar Continuous Theta Burst Stimulation in Essential Tremor. Cerebellum. 2014;14(2):133-141. https://doi.org/10.1007/s12311-014-0621-0
Zhao SJ, Cheng Rong-chuan, Zheng J, et al. A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson’s disease. Park Rel Dis. 2015;21(10):1214-1218. https://doi.org/10.1016/j.parkreldis.2015.08.023
Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson´s disease. Cochrane Database of Systematic Reviews. 2002;56:45935. https://doi.org/10.1002/14651858.cd003735
Barbeau A. The pathogenesis of Parkinson’s disease: a new hypothesis. Can Med Assoc J. 1962;87:802-807.
Sanchez-Catasus C, Bohnen NI, D’Cruz N, Muller M. Striatal acetylcholine-dopamine imbalance in Parkinson’s disease: in vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography. J Nucl Med. 2021;67:112-125.jnumed.121.261939. https://doi.org/10.2967/jnumed.121.261939
Moehle MS, Bender AM, Dickerson JW, et al. Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacol Transl Sci. 2021;4(4):1306-1321. https://doi.org/10.1021/acsptsci.0c00162
Moehle MS, Conn PJ. Roles of the M4 Acetylcholine Receptor in the Basal Ganglia and the Treatment of Movement Disorders. Mov Dis. 2019;34(8):1089-1099. https://doi.org/10.1002/mds.27740
Betz AJ, McLaughlin PJ, Burgos M, et al. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology. 2007;194(3):347-359. https://doi.org/10.1007/s00213-007-0844-6
Nuland AJM, Ouden HEM, Zach H, et al. GABAergic changes in the thalamocortical circuit in Parkinson’s disease. Human Brain Mapping. 2019;41(4):1017-1029. https://doi.org/10.1002/hbm.24857
Bullock AE, Kaul I, Li S, et al. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study. J Neurol Sci. 2021;421:117277. https://doi.org/10.1016/j.jns.2020.117277
Millan MJ. From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010;128(2):229-273. https://doi.org/10.1016/j.pharmthera.2010.06.002
Rondot P, Bathien N, Dumas JL. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications. Adv Neurol. 1975;9:373-381.
McLellan DL, Chalmers RJ, Johnson RH. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism. Acta Neurol Scand. 1975;51:74-82. https://doi.org/10.1111/j.1600-0404.1975.tb01360.x
Truelle JL, Chanelet J, Bastard J, et al. Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients. Nouv Presse Med. 1977;6:2987-2990.
Lieberman A, Le Brun Y, Zolfaghari M. Proceedings: effects of piribedil (ET 495)-a dopaminergic receptor stimulating agent in Parkinson’s disease. Psychopharmacol Bull. 1974;10:42-43.
Mentenopoulos G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson’s disease. Use of the drug in the retard form. Clin Neuropharmacol. 1989;12:23-28.
Ziégler M, Rondot P. Activité du piribédil dans la maladie de Parkinson. Etude multicentrique. Presse Med. 1999;28(26):1414-1418.
Suwantamee J, Nidhinandana S, Srisuwananukorn S, et al. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson’s disease: a 6-month open study. J Med Assoc Thai. 2004;87:1293-300.
Salazar TG, Wix RR, Salazar AP, et al. The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson’s disease: a nine month follow up. Rev Neurol. 2004;38:715-719.
Evidente VG, Esteban RP, Domingo FM, et al. Piribedil as an adjunct to levodopa in advanced Parkinson’s disease: the Asian experience. Park Relat Dis. 2003;10(2):117-121. https://doi.org/10.1016/s1353-8020(03)00096-8
Rascol O, Dubois B, Caldas AC, et al. Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. Mov Dis. 2006;21:2110-2115. https://doi.org/10.1002/mds.21122
Ziegler M, Castro-Caldas A, Del Signore S, et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: a 6-month, randomized, placebocontrolled study. Mov Disord. 2003;18:418-425. https://doi.org/10.1002/mds.10359
Peihua L, Jianqin W. Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson’s Disease: A Meta-Analysis. Open Med (Wars). 2018;13:270-277. https://doi.org/10.1515/med-2018-0041
Castro-Caldas A, Delwaide P, Jost W, et al. The ParkinsonControl study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord. 2006;21:500-509. https://doi.org/10.1002/mds.20750
Chen XT, Zhang Q, Chen FF, et al. Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson’s disease: a systematic review and network meta-analysis. Front Neurol. 2023;14:1183823. https://doi.org/10.3389/fneur.2023.1183823
Millan MJ, Cussac D, Milligan G, et al. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther. 2001;297:876-887.
Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther. 2003;305(1):338-346. https://doi.org/10.1124/jpet.102.046383

Close metadata